In breast cancer, hormonal receptors for estrogen (ER), progesterone (PR) and androgens (AR) can be used as a target for non-invasive whole-body evaluation of the hormonal status and to predict the response of cancer to endocrine treatment. The gene discussed is NR4A1; the disease is breast carcinoma.